Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials

Lixin Guo, Bin Zhang, Jianing Hou, Zhiguang Zhou, Lixin Guo, Bin Zhang, Jianing Hou, Zhiguang Zhou

Abstract

Introduction: Gastrointestinal (GI) events are a common side effect of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) class. This post hoc analysis assessed the characteristics of GI adverse events in Chinese patients with type 2 diabetes (T2D) who were treated with once-weekly dulaglutide from two randomized clinical trials.

Methods: Chinese patients with T2D, treated with once-weekly dulaglutide (1.5 mg and 0.75 mg) from two phase III multicenter trials (AWARD-CHN1 and AWARD-CHN2) were included. Descriptive statistics were used to present the data. The characteristics (incidence, severity, onset, duration, and time of occurrence) of GI adverse events reported through 26 weeks in a Chinese subpopulation from the two trials were investigated.

Results: A total of 787 Chinese patients with T2D were included in this analysis. Up to week 26, 225 patients (28.6%) reported at least one GI treatment-emergent adverse event (TEAE). The most frequently reported GI TEAEs were diarrhea (13.1%), nausea (6.6%), abdominal distension (6.4%), and vomiting (3.0%), with most being categorized as mild to moderate in severity in proportions of 92%, 88%, 94%, and 83%, respectively. A total of 12 patients (1.5%) discontinued the dulaglutide treatment as a result of GI TEAEs. The median duration of the first reported GI TEAEs was 4.0, 5.0, 12.5, and 4.0 days for diarrhea, nausea, abdominal distension, and vomiting, respectively. The incidence of GI TEAEs was more frequent during the first 2 weeks of dulaglutide treatment; however, the incidence declined rapidly after 2 weeks and remained low until week 26.

Conclusions: Most of the GI TEAEs associated with once-weekly dulaglutide (1.5 mg and 0.75 mg) were mild to moderate in severity. The incidence of GI TEAEs was more pronounced during the first 2 weeks of dulaglutide treatment but declined rapidly as treatment continued, and was low at week 26, indicating that dulaglutide was well tolerated in Chinese patients with T2D.

Trial registration: NCT01648582 and NCT01644500.

Keywords: Chinese patients; Dulaglutide; Gastrointestinal adverse events; Pooled analysis; Post hoc analysis; Type 2 diabetes.

Figures

Fig. 1
Fig. 1
Summary of time of occurrence of gastrointestinal treatment-emergent adverse events. N = 787 for all DU. DU dulaglutide, N total number of patients
Fig. 2
Fig. 2
Incidence of gastrointestinal adverse events from start of treatment (up to week 26). N = 787 for all DU. DU dulaglutide, N total number of patients

References

    1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023.
    1. Hu C, Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2018;67:3–11. doi: 10.2337/dbi17-0013.
    1. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7:354–395. doi: 10.4239/wjd.v7.i17.354.
    1. American Diabetes Association Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S98–S110. doi: 10.2337/dc20-S009.
    1. American Diabetes Association Cardiovascular disease and risk management: standards of medical care in diabetes—2020. Diabetes Care. 2020;Suppl 1:S103–S123. doi: 10.2337/dc19-S010.
    1. Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35:e3158. doi: 10.1002/dmrr.3158.
    1. Saisho Y. β-Cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015;6:109–124. doi: 10.4239/wjd.v6.i1.109.
    1. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15:15–27. doi: 10.1111/j.1463-1326.2012.01663.x.
    1. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260–1267. doi: 10.1111/j.1464-5491.2012.03745.x.
    1. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care. 2014;37:2159–2167. doi: 10.2337/dc13-2760.
    1. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) Diabetes Care. 2015;38:2241–2249. doi: 10.2337/dc14-1625.
    1. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care. 2014;37:2168–2176. doi: 10.2337/dc13-2759.
    1. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057–2066. doi: 10.1016/S0140-6736(15)60936-9.
    1. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care. 2014;37(8):2149–2158. doi: 10.2337/dc13-2761.
    1. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–1357. doi: 10.1016/S0140-6736(14)60976-4.
    1. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605–617. doi: 10.1016/S2213-8587(18)30104-9.
    1. Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8) Diabetes Obes Metab. 2016;18:475–482. doi: 10.1111/dom.12634.
    1. Pozzilli P, Norwood P, Jódar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9) Diabetes Obes Metab. 2017;19:1024–1031. doi: 10.1111/dom.12937.
    1. Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:370–381. doi: 10.1016/S2213-8587(18)30023-8.
    1. Shi LX, Liu XM, Shi YQ, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: post-hoc analyses of a randomized, double-blind, phase III study. J Diabetes Investig. 2020;11:142–150. doi: 10.1111/jdi.13075.
    1. Li Y, Li L, De Peng Y, et al. Efficacy and safety of dulaglutide versus insulin glargine in Chinese T2DM patients: a subgroup analysis of a randomized trial (AWARD-CHN2) Diabetes Ther. 2019;10:1435–1452. doi: 10.1007/s13300-019-0646-y.
    1. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck M. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19:336–347. doi: 10.1111/dom.12824.
    1. Ahrén B, Atkin SL, Charpentier G, et al. Semaglutide induces weight loss in subjects with type diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018;20:2210–2219. doi: 10.1111/dom.13353.
    1. World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925–926. doi: 10.1001/jama.1997.03540350075038.
    1. Krishnasamy S, Abell TL. Diabetic gastroparesis: principles and current trends in management. Diabetes Ther. 2018;9(Suppl 1):1–42. doi: 10.1007/s13300-018-0454-9.
    1. Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418–425. doi: 10.1111/j.1463-1326.2011.01366.x.
    1. Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract. 2012;66:1021–1032. doi: 10.1111/j.1742-1241.2012.03006.x.
    1. Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: incidence and consequences. Diabetes Obes Metab. 2017;19:672–681. doi: 10.1111/dom.12872.
    1. Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab. 2018;20:2121–2130. doi: 10.1111/dom.13340.
    1. Wang W, Nevárez L, Filippova E, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019;21:234–243. doi: 10.1111/dom.13506.
    1. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract. 2009;83:69–76. doi: 10.1016/j.diabres.2008.09.037.
    1. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab. 2011;13:81–88. doi: 10.1111/j.1463-1326.2010.01323.x.
    1. Kugler AJ, Thiman ML. Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes Metab Syndr Obes. 2018;11:187–197. doi: 10.2147/DMSO.S134960.
    1. Sun F, Yu K, Yang Z, et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res. 2012;2012:230624. doi: 10.1155/2012/230624.
    1. Thazhath SS, Marathe CS, Wu T, et al. The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes. 2016;65:269–275.
    1. Inoue M, Shiramoto M, Oura T, Nasu R, Nakano M, Takeuchi M. Effect of once-weekly dulaglutide on glucose levels in Japanese patients with type 2 diabetes: findings from a phase 4, randomized controlled trial. Diabetes Ther. 2019;10:1019–1027. doi: 10.1007/s13300-019-0605-7.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa